Gene Therapy Drugs Market
Gene Therapy Drugs Market Scope: Industry
Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Gene Therapy Drugs Market Size and Growth
The Gene Therapy Drugs market is poised for significant growth, driven by increasing advancements in genetic research and rising prevalence of genetic disorders. The market size is projected to reach approximately $10 billion by 2025, fueled by innovative therapies and expanded regulatory approvals. Competitive landscapes are evolving with numerous ongoing clinical trials. Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ F. Hoffmann-La Roche AG
◍ Bluebird Bio
◍ Ultragenyx Pharmaceutical ， Inc.
◍ Novartis International AG
◍ BioMarin Pharmaceutical
◍ Gilead Sciences, Inc.
◍ Sangamo Therapeutics
◍ Audentes Therapeutics
◍ Applied Genetic Technologies Corp
◍ Nightstar Therapeutics
◍ Spark Therapeutics
◍ Voyager Therapeutics
◍ uniQure
◍ VBL Therapeutics
The gene therapy drugs market features companies like Roche, Bluebird Bio, Ultragenyx, Novartis, and Gilead, driving growth through innovative therapies targeting genetic disorders. Their research, partnerships, and successful product launches enhance market presence. Sales revenue examples include:
- Novartis: $12 billion (2022)
- Gilead: $27 billion (2022)
Request Sample Report
Market Segmentation
By Application
Hospital
Pharmacy
Request Sample Report
By Product
Neuromuscular Disease
Genetic Disease
Other
Market Growth
Request Sample Report
$ X Billion USD
